NASDAQ:ICCM IceCure Medical (ICCM) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free ICCM Stock Alerts $1.22 +0.03 (+2.37%) (As of 09:46 AM ET) Add Compare Share Share Today's Range$1.20▼$1.2250-Day Range$1.18▼$1.3752-Week Range$0.52▼$1.57Volume15,085 shsAverage Volume635,160 shsMarket Capitalization$55.57 millionP/E RatioN/ADividend YieldN/APrice Target$2.95 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get IceCure Medical alerts: Email Address IceCure Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside145.7% Upside$2.95 Price TargetShort InterestHealthy1.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 starsMedical Sector447th out of 908 stocksSurgical & Medical Instruments Industry52nd out of 97 stocks 3.5 Analyst's Opinion Consensus RatingIceCure Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIceCure Medical has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.50% of the float of IceCure Medical has been sold short.Short Interest Ratio / Days to CoverIceCure Medical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IceCure Medical has recently decreased by 15.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIceCure Medical does not currently pay a dividend.Dividend GrowthIceCure Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICCM. Previous Next 3.1 News and Social Media Coverage News SentimentIceCure Medical has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IceCure Medical this week, compared to 1 article on an average week.Search Interest8 people have searched for ICCM on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IceCure Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.44% of the stock of IceCure Medical is held by insiders.Percentage Held by InstitutionsOnly 0.62% of the stock of IceCure Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IceCure Medical are expected to grow in the coming year, from ($0.28) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IceCure Medical is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IceCure Medical is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIceCure Medical has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About IceCure Medical Stock (NASDAQ:ICCM)IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Read More ICCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICCM Stock News HeadlinesApril 19, 2024 | finance.yahoo.comHofseth Biocare ASA: HBC ANNUAL REPORT 2023April 17, 2024 | americanbankingnews.comIceCure Medical (NASDAQ:ICCM) Receives Buy Rating from HC WainwrightApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 15, 2024 | finance.yahoo.comIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerApril 6, 2024 | markets.businessinsider.comIcecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory MilestonesApril 5, 2024 | seekingalpha.comIceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call TranscriptApril 4, 2024 | uk.investing.comIceCure seeks FDA clearance for new cryoablation systemApril 3, 2024 | prnewswire.comIceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing ClearanceApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 2, 2024 | prnewswire.comIceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with CryoprobesMarch 27, 2024 | prnewswire.comIceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024March 19, 2024 | markets.businessinsider.comIceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive ResultsMarch 19, 2024 | finance.yahoo.comIceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to LumpectomyMarch 12, 2024 | prnewswire.comIceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient OutcomesMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 5, 2024 | markets.businessinsider.comIceCure Medical: Strong Buy on Promising Clinical Results and Positive FDA DevelopmentsMarch 4, 2024 | prnewswire.comIceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024February 27, 2024 | prnewswire.comFourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions WorkshopFebruary 26, 2024 | prnewswire.comStudy Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast CancerFebruary 24, 2024 | msn.comIceCure Medical (ICCM) Price Target Increased by 5.85% to 3.14February 15, 2024 | finance.yahoo.comIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in JapanFebruary 15, 2024 | prnewswire.comIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in JapanJanuary 30, 2024 | msn.comFDA agrees to review IceCure request for De Novo classificationJanuary 30, 2024 | finance.yahoo.comU.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast CancerJanuary 29, 2024 | finance.yahoo.comIceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master ClassJanuary 16, 2024 | finance.yahoo.comIceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of CryoablationSee More Headlines Receive ICCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IceCure Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2024Today4/25/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:ICCM CUSIPN/A CIK1584371 Webwww.icecure-medical.com Phone972-4623-0333Fax972-4623-0222Employees65Year FoundedN/APrice Target and Rating Average Stock Price Target$2.95 High Stock Price Target$3.00 Low Stock Price Target$2.90 Potential Upside/Downside+147.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net Margins-453.76% Pretax Margin-453.76% Return on Equity-86.96% Return on Assets-68.63% Debt Debt-to-Equity Ratio0.03 Current Ratio3.66 Quick Ratio3.08 Sales & Book Value Annual Sales$3.23 million Price / Sales16.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.41Miscellaneous Outstanding Shares45,620,000Free Float44,510,000Market Cap$54.29 million OptionableNot Optionable Beta0.73 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Eyal Shamir (Age 63)CEO & Director Comp: $467.32kMr. Ronen Tsimerman CPA (Age 55)CFO & COO Comp: $331.8kMs. Tlalit Bussi Tel-Tzure (Age 53)Vice President of Business Development & Global Marketing Comp: $279.34kMs. Merav Nir Dotan (Age 55)Vice President of Human Resources Comp: $197.96kMs. Galit Malik (Age 51)Vice President of Operations & Service Key CompetitorsSensus HealthcareNASDAQ:SRTSAutonomix MedicalNASDAQ:AMIXSEP AcquisitionNASDAQ:SEPAHealth Sciences Acquisitions Co. 2NASDAQ:HSAQCytosorbentsNASDAQ:CTSOView All Competitors ICCM Stock Analysis - Frequently Asked Questions Should I buy or sell IceCure Medical stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICCM shares. View ICCM analyst ratings or view top-rated stocks. What is IceCure Medical's stock price target for 2024? 2 Wall Street analysts have issued 12 month price targets for IceCure Medical's stock. Their ICCM share price targets range from $2.90 to $3.00. On average, they anticipate the company's share price to reach $2.95 in the next twelve months. This suggests a possible upside of 145.7% from the stock's current price. View analysts price targets for ICCM or view top-rated stocks among Wall Street analysts. How have ICCM shares performed in 2024? IceCure Medical's stock was trading at $1.07 at the beginning of 2024. Since then, ICCM shares have increased by 12.2% and is now trading at $1.2006. View the best growth stocks for 2024 here. Are investors shorting IceCure Medical? IceCure Medical saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 299,800 shares, a drop of 15.2% from the March 31st total of 353,600 shares. Based on an average daily trading volume, of 684,500 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.5% of the company's shares are short sold. View IceCure Medical's Short Interest. When is IceCure Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our ICCM earnings forecast. How were IceCure Medical's earnings last quarter? IceCure Medical Ltd (NASDAQ:ICCM) announced its quarterly earnings results on Wednesday, April, 3rd. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $1.26 million for the quarter. IceCure Medical had a negative trailing twelve-month return on equity of 86.96% and a negative net margin of 453.76%. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. How do I buy shares of IceCure Medical? Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ICCM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IceCure Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
